Medicine's Big Bottleneck

Medicine’s Big Bottleneck If health care companies and the U.S. government do not tread carefully, concerns about the cost of developing and providing treatments could derail medical innovation. That was the consensus among top industry and regulatory figures yesterday during speeches and interviews at the Medical Innovations Summit at the Cleveland Clinic.


Medicine’s Big Bottleneck

Medicine’s Big Bottleneck If health care companies and the U.S. government do not tread carefully, concerns about the cost of developing and providing treatments could derail medical innovation. That was the consensus among top industry and regulatory figures yesterday during speeches and interviews at the Medical Innovations Summit at the Cleveland Clinic.


Stem cell bill eyed as lure to biotech firms

Stem cell bill eyed as lure to biotech firms A redraft may be in its future, but supporters of a proposed Bay State bill filed last winter that would formally welcome and set boundaries for stem cell research here say the measure will be an important part of the legislative agenda in the coming months.


Do NOT follow this link or you will be banned from the site!
%d bloggers like this: